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Background: The evolving epidemiology of methicillin resistant Staphylococcus aureus (MRSA) is characterized
by the emergence of infections caused by non multiresistant MRSA carrying staphylococcal chromosomal
cassette (SCC)mec IV or V in the healthcare settings. A molecular epidemiological analysis of non
multiresistant MRSA isolates from four acute general hospitals was performed in Palermo, Italy, during a one
year period.
Methods: For the purpose of the study, MRSA isolates were defined as non multiresistant when they were
susceptible to at least three classes of non β-lactam antibiotics. Seventy-five isolates were submitted to
antimicrobial susceptibility testing, multilocus sequence typing (MLST) and polymerase chain reaction (PCR) for
SCCmec, accessory gene regulator (agr) groups, arginine catabolic mobile element (ACME) and Panton
Valentine leukocidin (PVL) toxin genes. For epidemiological typing, Multiple-Locus Variable-Number Tandem
Repeat Fingerprinting (MLVF) was performed on all isolates and pulsed field gel electrophoresis (PFGE) on ST8
isolates.
Results: Non multiresistant MRSA isolates were isolated from all hospitals. Resistances to ciprofloxacin,
macrolides and tetracycline were the most prevalent. MLST attributed 46 isolates with ST22, 13 with ST8,
eight with ST1, three with ST50 and three with ST398. SCCmec type IV was found in all isolates. PVL was
detected in one ST22 isolate. All isolates tested negative for the ACME element. MLVF identified 31 different
patterns, some subtype clusters ranging in size between two and 22 isolates. The closely related PFGE
patterns of the ST8 isolates differed from USA300.
Conclusions: A polyclonal circulation of non multiresistant MRSA along with blurring of boundaries between
healthcare associated (HA)-MRSA and community associated (CA)-MRSA appear to be occurring in our
epidemiological setting. A better understanding of spread of MRSA with the support of molecular typing can
provide invaluable information in the epidemiological, microbiological and clinical fields.* Correspondence: caterina.mammina@unipa.it
Department of Sciences for Health Promotion “G. D’Alessandro”, University of
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Methicillin resistant Staphylococcus aureus (MRSA) is a
leading cause of disease, such as skin and soft tissue in-
fection (SSTI), pneumonia, bloodstream infection (BSI),
osteomyelitis and endocarditis, as well as toxin-mediated
syndromes [1]. MRSA is unquestionably one of the most
important nosocomial pathogens worldwide, but re-
cently it is increasingly identified as the etiological agent
of infections acquired in community [1,2]. Although evi-
dence has accumulated suggesting that some strains of
community associated (CA)-MRSA might have spilled from
healthcare setting in the community, molecular epidemio-
logical studies indicate that CA-MRSA and healthcare asso-
ciated (HA)-MRSA may have distinctive phenotypic and
genetic features [1,2]. Traditionally, CA-MRSA are attribu-
ted with characteristics, such as smaller staphylococcal
chromosomal cassette (SCC)mec cassettes – types IV
and V – and a more restricted resistance pattern to anti-
biotics other than β-lactams than HA-MRSA [3]. How-
ever, recently, a bidirectional crossing of borders between
HA- and CA-associated infections is occurring, with
HA-MRSA clones being responsible for infections in com-
munity and, vice versa, CA-MRSA causing infections in
hospitalized patients [4]. The changing epidemiology of
MRSA is also been characterized by the emergence of
infections caused by non multiresistant MRSA carrying
SCCmec IV or V in the healthcare settings [3,5].
This study had the aim to perform a molecular epi-
demiological analysis of all non multiresistant MRSA
isolates carrying SCCmecIV from out- and inpatients ad-
mitted to all wards of four acute general hospitals in Pa-




This study was conducted in the period February 1,
2009 – January 31, 2010 with the collaboration of the
clinical microbiology laboratories of three acute general
hospitals and one teaching hospital in Palermo, Italy.
Overall, isolates from 179 inpatients and ambulatory
outpatients were collected and sent to the coordinating
laboratory at the Department of Sciences for Health Pro-
motion “G. D’Alessandro”, University of Palermo, Italy.
Only one isolate per patient was included in the study.
In particular, all the unique isolates were analyzed. In
the event of multiple consecutive isolations from the
same patient, only the first isolate since the admission
was included. Isolates from infection control screening
specimens were excluded.
Information about ward and type of biological sample
was obtained, whereas clinical and epidemiological infor-
mation regarding patient’s risk factors and previous or on-
going antimicrobial therapy was generally unavailable.At the coordinating laboratory, all MRSA isolates were
sub-cultured for purity on mannitol-salt agar. Their identi-
fication was confirmed by biochemical tests, coagulase
production and the cefoxitin disk diffusion test, according
with the interpretive criteria of the Clinical and Laboratory
Standards Institute (CLSI) [6]. Submitted isolates exhibit-
ing equivocal results were confirmed by detection of mecA
gene by use of polymerase chain reaction (PCR). The iso-
lates were stored in glycerol at −70°C.
For the purpose of the study, MRSA isolates were
defined as non multiresistant when they were susceptible
to at least three classes of non β-lactam antibiotics (ami-
noglycosides, fluoroquinolones, macrolides, rifampicin,
sulfamethoxazole-trimethoprim, tetracyclines).
Multilocus sequence typing (MLST)
MLST was performed, as previously described, for a
selected group of representative strains of each MLVF pat-
tern [7]. The MLST allelic profiles and sequence types
were assigned by submission to the S. aureus MLST data-
base (www.mlst.net).
Polymerase chain reaction (PCR)
Determination of SCCmec types was performed by
multiplex PCR, according with Zhang et al. [8] and
Milheiriço et al. [9]. Accessory gene regulator (agr) spe-
cificity grouping was carried out for all MRSA isolates
[10]. MRSA isolates were further defined by the pres-
ence of arginine catabolic mobile element (ACME) and
the Panton-Valentine leukocidin (PVL) toxin genes by
PCR for arcA and lukS-PV, respectively [11]. An
USA300 reference strain was kindly provided by Prof. S.
Stefani, Molecular Microbiology and Antibiotic Resist-
ance Lab, Department of Microbiology, University of
Catania, Catania, Italy, and included in the analysis.
Antimicrobial susceptibility testing
Participating laboratories provided susceptibility patterns
obtained by their routine methods. Minimum inhibitory
concentrations of vancomycin, teicoplanin, tigecycline,
daptomycin and linezolid were re-assessed by Etest (AB
Biodisk, Solna, Sweden). All assays were performed and
interpreted in accordance with Clinical and Laboratory
Standards Institute (CLSI) guidelines [6].
Multiple-locus variable-number tandem repeat
fingerprinting (MLVF)
The set of PCR primers described by Sabat et al. [12]
was used to simultaneously amplify the hypervariable
variable number tandem repeat (VNTR) regions of the
spa, sspA, clfA, clfB and sdr genes with the modifications
proposed by Karinsky et al. [13]. Amplification and gel
electrophoresis conditions were as previously described
[12]. The MLVF patterns were analyzed by using
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Martens Latem, Belgium). A dendrogram was produced
by using Dice coefficients and unweighted pair-group
method using geometric averages (UPGMA), with 0.5%
optimization and 1.25% band position tolerance [13].
The results obtained were confirmed by visual inspec-
tion. Any two MLVF patterns differing by at least one
band were considered distinct types and attributed with
sequential numerical codes.
Pulsed field gel electrophoresis (PFGE)
ST8 MRSA isolates representative of the different MLVF
patterns and the USA300 reference strain were geno-
typed by PFGE after SmaI digestion of chromosomal
DNA, prepared using the protocol described by Cookson
et al. [14] with slight modifications. The banding pat-
terns were visually assessed and interpreted according
with previously published criteria [15].
Results
In the period under study, 75 (41.9%) non multiresistant
MRSA isolates were identified among a total of 179 iso-
lates from the four hospitals participating to the study.
Non multiresistant MRSA isolates were isolated from all
hospitals: 28 each from the hospitals A and D, 11 from
the hospital C and eight from the hospital B, respect-
ively. Thirty-six were isolated from inpatients admitted
to medical wards, 21 from intensive care unit (ICU)
patients, nine from surgical patients, and four only from
outpatients. As summarized in Table 1, the most com-
mon sites of infection were respiratory tract (28 cases),
skin and soft tissues (23 cases), and bloodstream (10
cases). In five cases, no information about the clinical
sample was available.
MLST showed that 46 isolates belonged to ST22, 13 to
ST8, eight to ST1, three to ST50 and three to the live-
stock associated MRSA (LA-MRSA) ST398 clone. Two
further isolates proved to belong to ST1517, a singleTable 1 Distribution of the sites of infection among the
different sequence types (STs) of the MRSA isolates
under study
Site of infection No. of isolates
ST1 ST8a ST22 ST50 ST398
Respiratory tract 5 8 13 1 1
Skin and soft tissues 2 3 16 - 2
Bloodstream - 3 6 2 -
Eye - - 3 - -
Surgical site 1 - 2 - -
Urinary tract - 1 1 - -
Unknown - - 5 - -
a including ST1517.locus variant (SLV) of ST8. CA-MRSA belonging to the
major European clone ST80 were not identified.
As detailed in Table 1, SCCmec type IV was found in
all MRSA isolates. The most common profile was
SCCmec subtype IVa (51 isolates, 68.0%), followed by
SCCmec IVb (13 isolates) and SCCmec IVc (11 isolates).
Thirty-three out of 46 isolates, belonging to ST22-IV
(EMRSA-15) carried SCCmec IVa, whilst the remaining
13 SCCmec IVb. Furthermore, SCCmec IVc was identi-
fied in most ST8-IV isolates (11 out of 15 isolates) and
SCCmec IVa in the four remaining isolates, including
those attributed with ST1517. All ST1, ST50 and ST398
isolates carried the subtype SCCmec IVa.
ST22, ST8 and ST398 isolates belonged to agr group I,
whereas ST1 and ST50 isolates were attributed, respect-
ively, with agr groups III and IV. PVL was detected in
only one isolate belonging to ST22 from a SST infection.
All isolates tested negative by PCR for the arcA locus of
the ACME element.
Table 2 illustrates the resistance profiles of the MRSA
strains under study. In particular, 36 isolates (48.0%)
were resistant to ciprofloxacin, 35 (46.7%) to chlarytro-
mycin, 32 (42.7%) to erythromycin, and 23 (30.7%) to
tetracycline. Resistance to gentamicin (five isolates),
sulfamethoxazole-trimethoprim (three isolates) and ri-
fampicin (three isolates) proved to be less frequent. All
strains tested susceptible to vancomycin, teicoplanin,
linezolid, daptomycin and tigecycline. Twenty-three out
of 46 of the ST22 isolates and 13 out of 15 ST8/ST1517
isolates proved to be resistant to ciprofloxacin, in com-
parison with none of ST1 and ST50 isolates. One ST398
isolate was also ciprofloxacin resistant. Resistance to
macrolides was also frequent and associated with some
clustered isolates, such as ST22-MRSA-IVb MLVF 023
and 073, and those belonging to ST1.
To obtain a more discriminative picture of the MRSA
strains in the four hospitals under study and highlight
possible subtype clusters of epidemiological interest, all
MRSA were submitted to MLVF. This fingerprinting
technique allowed for the identification of 31 different
banding patterns among the 75 isolates under study
(Table 2 and Figure 1). Some subtype clusters were also
recognized ranging in size between two and 22 isolates.
In particular, the largest subtype cluster, including 22
isolates, was characterized by the MLVF pattern 004 and
was found within the ST22-IVa isolates. It comprised
isolates with six different antibacterial susceptibility pat-
terns from all the participating hospitals. Moreover, two
smaller clusters, grouping seven and six isolates, respect-
ively, were identified among the ST22-IVb isolates: the
first one, characterized by the MLVF pattern 023 con-
tained isolates from three out of the four hospitals under
investigation, whereas the second one with the MLVF
pattern 073 consisted of isolates that, except for one of
Table 2 Distribution of the MRSA isolates on the basis of the molecular epidemiological characterization and pattern
of resistance to non β-lactam antibiotics
No. of isolates STa SCCmec type No. of isolates Resistance profileb MLVFc type
46 22 IVa 10 TET 004
2 CLR TET 004
2 CIP 004
1 CIP TET 004
1 GM TET 004
6 susceptible 004
1 CIP SXT 009
1 CIP CLR ERY 017
1 CIP CLR ERY 019
1 susceptible 024
1 susceptible 043
1 CIP CLR ERY 058
1 CIP 059
1 SXT TET 060
1 CIP ERY 061
1 CIP 068
1 TET 070
IVb 7 CIP CLR ERY 023
5 CIP CLR ERY 073
1 CIP CLR ERY SXT 073
13 8 IVc 2 CIP CLR ERY 006
2 CIP 044
2 CIP CLR ERY 044
1 CIP ERY 012
1 CIP GM RIF 018
1 CIP ERY 035
1 CIP CLR ERY GM 045
1 CIP 064
IVa 1 susceptible 003
1 CIP CLR ERY 045
8 1 IVa 3 CLR ERY TET 065
2 CLR ERY TET 033
1 CLR ERY 010
1 CLR ERY 040
1 CLR TET 049
3 50 IVa 2 susceptible 030
1 susceptible 002
3 398 IVa 1 CLR GM RIF TET 029
1 CIP TET 029
1 GM RIF TET 029
2 1517 IVa 2 CLR 057
a ST, sequence type.
b other than β-lactams.
CLR, clarithromycin; CIP, ciprofloxacin; ERY, erythromycin; GM, gentamicin; RIF, rifampicin; SXT, sulfamethoxazole- trimethoprim; TET, tetracycline.
c MLVF, Multiple-Locus Variable-Number Tandem Repeat Fingerprinting.
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Figure 1 Dendrogram showing similarity between the 31 different Multiple-Locus Variable-Number Tandem Repeat Fingerprinting
(MLVF) patterns. Sequence type (ST) is also indicated.
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wards of the same hospital.
No significant subtype clusters were identified among
the ST8/ST1517-IV isolates. Three couples of strainswith identical MLVF patterns and drug resistance pro-
files were indeed recognized, but four of them, showing
the profile 044, came from different hospitals. The two
isolates ST1517 shared the same MLVF profile 057, but
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an inpatient and an outpatient, respectively, without any
meaningful epidemiological correlation.
Of special interest, an indistinguishable MLVF pattern
was shared by three ST398-MRSA-IVa isolates. They were
identified several months apart from each other (February
2009, July 2009 and January 2010) at the same hospital
from a patient with ventilator-associated pneumonia and
two further patients with serious SST infections.
The ST8 MRSA isolates shared indistinguishable or
closely related PFGE banding patterns, but distinctly dif-
ferent from that of USA300 strain.
Discussion
MRSA is one of the most prevalent pathogens isolated
from hospitalized patients and is increasingly identified
in outpatient settings. Along with the spread of some
multiresistant clones in the healthcare settings, emer-
gence of CA-MRSA is cause of major concern for both
clinicians and public health specialists [3]. Blurring of
boundaries between HA-MRSA and CA-MRSA is a fur-
ther challenge predominantly arising from changes in
the hospitalized patients management. This involves
increased bed turnover and patient throughput and the
more and more complex patterns of transfer of patients
within the healthcare network including teaching and
non teaching hospitals, long term care facilities, nursing
homes, home care and other alternative healthcare set-
tings [4]. Moreover, the selective pressure operated by
antibiotic use is likely contributing also to the acquisi-
tion and/or loss of virulence genes carried on mobile
genetic elements that can easily spread within and be-
tween lineages [16].
SCCmec cassette IV and a non multiresistant pattern
of drug susceptibility generally characterize some well
known clones of HA-MRSA, such as ST22-MRSA-IV, a
pandemic CC22-MRSA strain known as (UK-)EMRSA-
15, and the CA-MRSA strains. It has been, on the other
hand, debated about the ecological advantage in terms
of bacterial fitness provided to these strains by a “light”
SCCmec cassette, that in part could explain their world-
wide successful spread [17,18].
In our one-year surveillance period, ST22-MRSA-IV
proved to be the most prevalent non multiresistant clone
in Palermo, Italy. It was identified, indeed, in all the hospi-
tals under investigations, in many different wards and clin-
ical samples. It proved also to include as much as 20
different strains based upon their MLVF banding and drug
susceptibility patterns. It is noteworthy also that during
the surveillance period an outbreak of colonization/infec-
tion by EMRSA-15 with the MLVF pattern 004 occurred
in the NICU of one out of the four hospitals [19].
EMRSA-15 emerged in the United Kingdom in 1991,
spread widely, and in the following years accounted formore than 90% of MRSA isolates [20]. It is being detected
in hospitals as well as in outpatients in several geographic
areas, such as Europe, where it appears to be replacing
previous established clones. Indeed, EMRSA-15 has been
found in a number of hospitals in the Netherlands [21], in
the Czech Republic [22], in Portugal [23], as well as in
Malta [24]. EMRSA-15 has been also previously described
as an emerging clone in some Italian regions [25]. Ability
of strains belonging to this clone to survive long time on
inanimate surfaces is likely providing a better opportunity
to spread within healthcare settings and toward the com-
munity than other HA-MRSA clones [26]. A role has been
also suggested for the diffusely increasing use of fluoroqui-
nolones that is likely exerting a selective pressure favoring
the emergence of MRSA strains that are usually resistant
to these drugs, such as EMRSA-15 [27]. However, accord-
ing with previous reports [28], ciprofloxacin susceptibility
was not a so infrequent event, involving 50% of the ST22
strains. As a consequence, when screening for MRSA by
using ciprofloxacin-containing selective media, caution is
to be adopted. Consistently with reports from other coun-
tries [29,30], but unlikely from previous data from Italy
[25], in our experience the only MRSA isolate that tested
positive to PVL proved to belong to ST22.
The second most represented clone in our surveillance
study was ST8-MRSA-IV. Clonal type ST8 associated with
different SCCmec types has been previously described
mainly in association with CA-MRSA strains. However,
all of our strains were pvl/arcA negative and had
PFGE pattern not identical to that of USA300. Thus,
on the basis of their genetic characteristics, the ST8
isolates were presumed to belong to the HA-MRSA
epidemic clone (UK) EMRSA-2/6 [31]. Resistance to
ciprofloxacin is also consistent with previous reports
about this clone [32]. ST8-MRSA-IV isolates with similar
characteristics have been recently reported in a collection
of isolates from 19 Italian hospitals in the 2000’s [33], as
well as in other countries of the European area, such as
Netherlands, [34] and of the Mediterranean basin, such as
Israel [31,34].
ST1-MRSA-IV is a community associated clone. It has
been recently documented as the most frequently identi-
fied PVL positive MRSA clone in skin and soft tissue
infections in some communities of northern Canada
[35]. However, PVL negative strains also have been
reported to cause serious infections in high risk groups
such as intravenous drug users [36]. In our experience,
ST1 isolates appeared to be associated not only to SSTIs,
but mainly to respiratory tract infections. They appeared
also rather homogeneous by drug susceptibility pattern
and MLVF banding profiles. At our best knowledge this
is the first report of healthcare associated human infec-
tions by ST1-MRSA-IVa in Italy. Interestingly, ST1
strains but with distinctive properties, such as several
Mammina et al. Annals of Clinical Microbiology and Antimicrobials 2012, 11:17 Page 7 of 9
http://www.ann-clinmicrob.com/content/11/1/17virulence and resistance genes towards major classes of
antimicrobials, SCCmec type V and peculiar PFGE pat-
terns, have been recently reported to circulate in hold-
ings of breeding pigs in Italy [37].
Similar considerations can be done about the first de-
tection in Italy of three isolates of ST50-MRSA-IVa, a
further CA-MRSA clone, that has been identified in hos-
pitalized patients during the period under study. Al-
though for two out of them with a MLVF pattern 030,
that had been isolated in two patients in the same ward
one month distant from each other, a intrahospital
cross-transmission event could be reasonably hypothe-
sized, presence of this additional CA-MRSA clone in the
hospital setting is cause of further concern.
A special attention deserves the identification within
the MRSA isolates recovered during the one-year period
of surveillance of three ST398-MRSA-IVa strains. It has
become apparent since some years that livestock consti-
tutes a reservoir for this MRSA clone and can be a po-
tential source of transmission to humans [1-3]. In
particular, the frequent colonization of livestock with
MRSA in many European countries is a cause for great
concern, even if knowledge and understanding mechan-
isms of emergence and spread of these organisms and
their public health implications are still preliminary.
According with some authors, attributing mechanically
human infections with S. aureus ST398 to livestock
reservoirs at this time still needs prudence and the hy-
pothesis that ST398 variants might persist in humans
without livestock contact cannot be discharged [38].
Possible role as ST398 MRSA vehicle of meat or other
food products of animal origin is under scrutiny [39].
Prevalence of ST398 MRSA within the clinical isolates
under study was 1.7%, a similar proportion to that re-
cently reported for some European countries, such as
Austria and Denmark [40]. In our experience, ST398-
MRSA-IVa was isolated from three different patients, of
whom two outpatients, without any epidemiological re-
lationship between each other. Of further concern, two
of them reported no history of livestock or pet exposure.
MLVF was thoroughly adopted for epidemiological
typing based upon previous reports confirming stability
and adequacy of the method to a broad use in detection
of outbreaks and potential sources of transmission
[12,41] and its high discriminatory power [41,42]. Add-
itionally, the MLVF method is a cost-effective and
speedy tool suitable for application in routine microbiol-
ogy laboratories already applying PCR-based assays. Our
data confirm the ability of MLVF to subtype the more
prevalent MRSA lineages. In particular it was able to
distinguish between subtypes of ST22 an ST8 and unam-
biguously identify ST398 strains.
To conclude, some considerations arise from the results
of our study:– circulation of non multiresistant MRSA in our
epidemiological setting proved to be polyclonal
– epidemiology of MRSA is evolving in our geographic
area toward the blurring of boundaries between HA-
MRSA and CA-MRSA, that has been largely
documented in other developed countries. Detection
of “true” CA-MRSA clones, such as ST1 or ST50 in
inpatients is a clear evidence of this ongoing
phenomenon deserving further strict monitoring
– because of the high prevalence of EMRSA-15,
detection of SCCmecIV is not a good predictor of
CA-MRSA
– PVL-negative CA-MRSA strains are circulating in
hospitalized patients in western Sicily, a finding that
has been previously described in other Italian
regions. Virulence of these strains is reasonably
expected to be lower, but understanding of clinical
and epidemiological implications of this event is still
very limited
– recovery of ST398 from three human cases of
infections, two of whom with a negative history of
contact with livestock, adds a further element of
concern.
Conclusions
Understanding epidemiology of MRSA is indispensable
to guide targeted initiatives to control spread of these
organisms in the healthcare settings and the community.
Surveillance of MRSA clones by using molecular typing
can provide invaluable information in the epidemio-
logical, microbiological and clinical fields. In this respect,
local epidemiological data may support control efforts
aimed at interrupting the spread within and between dif-
ferent healthcare settings and between these and the
community. Concurrently, they may contribute to build
and update surveillance databases at both national and
international levels.
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